Olfr810 is a member of the olfactory receptor (OR) family, which falls under the category of G protein-coupled receptors (GPCRs), essential for the sense of smell. These receptors, including Olfr810, are specialized in detecting specific odorant molecules and initiating the olfactory signal transduction pathway. The activation process of olfactory receptors typically entails the binding of odorant molecules, which induces conformational changes in the receptor. These changes allow interaction with G proteins, leading to a cascade of intracellular signaling events that culminate in the perception of odors. The specific ligands and broader physiological functions of Olfr810 are not completely elucidated, indicative of the complexity inherent in the study of olfactory receptors due to their highly specific and diverse ligand affinities. The activation mechanisms of Olfr810, like other GPCRs, are subject to modulation by various cellular factors. A pivotal regulatory mechanism in GPCR function involves the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP, acting as a secondary messenger, plays a crucial role in numerous cellular functions, including GPCR signaling. The synthesis of cAMP is catalyzed by adenylate cyclase, which converts ATP into cAMP in response to external stimuli.
Phosphodiesterases (PDEs), responsible for the breakdown of cAMP, play a critical role in regulating its intracellular concentration. Inhibiting PDEs can lead to an increase in cAMP within the cell, indirectly affecting GPCR signaling. This elevation in cAMP, resulting from PDE inhibition, can indirectly modulate the activity of Olfr810 through various mechanisms, including changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Furthermore, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr810. These interactions demonstrate the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of receptors like Olfr810 indirectly. In summary, the study of Olfr810 activation offers essential insights into the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The intricate interplay between different cellular components and signaling molecules, along with the potential for modulation by external compounds, underscores the complexity and significance of these receptors in sensory perception and cellular communication.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, sourced from Coleus forskohlii, activates adenylate cyclase, increasing cAMP levels. Elevated cAMP can modulate GPCR signaling, potentially affecting Olfr810 activity by enhancing receptor phosphorylation and sensitivity via PKA-mediated pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, elevates intracellular cAMP via adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr810 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, raises cAMP and cGMP levels, potentially influencing Olfr810 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors, increasing cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr810 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, increases cAMP levels. Elevated cAMP may enhance Olfr810 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr810 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $92.00 $138.00 | ||
Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This increase might boost Olfr810 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $31.00 $83.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr810 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr810 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr810 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. |